Online inquiry

IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9893MR)

This product GTTS-WQ9893MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets pcrV gene. The antibody can be applied in Cystic Fibrosis (CF) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9893MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4913MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ11323MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ8458MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ2834MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ1417MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ9350MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ15490MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ11227MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI3902
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW